Is Medplus Health Services (MEDPLUS) overvalued or fairly valued?

MarketChacha shows Medplus Health Services's valuation in context — a forward P/E of about 27.1, a price-to-book of about 4.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Medplus Health Services's revenue?

Medplus Health Services reported revenue of ₹6,892 Cr for FY2026, with net profit of ₹220 Cr, per official filings.

What is the share price of Medplus Health Services (MEDPLUS)?

Medplus Health Services last traded at ₹691.95 (-13.6% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Medplus Health Services

MEDPLUS · NSE · Healthcare · India

₹691.95-13.6%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 10:00 AM

Snapshot

TickerMEDPLUS

ExchangeNSE

SectorHealthcare

IndustryPharmaceutical Retailers

CountryIndia

HeadquartersHyderabad, India

Market cap₹8,309 Cr

P/B4.2

Volume24.31L

Websitewww.medplusindia.com

Filings tracked2

About Medplus Health Services

MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters41.7%
Institutions35.1%
Public & other23.2%

52 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend1.1% → 3.2%

Margin has expanded by about 2.1 points — the business is getting more profitable.

Growth qualityrev 15% · PAT 64%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹9,117 Cr · EPS 25.54

Est. earnings growth +15.6%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹653.0052-wk range₹1,022.20

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹8,309 Cr

Day change

-13.6%

Fwd P/E

27.1

P/B

4.2

Beta

0.44

Revenue (FY2026)

₹6,892 Cr

Net margin

3.2%

Revenue CAGR (3y)

+14.8%

Profit CAGR (3y)

+64.0%

Net profit (FY2026)

₹220 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about MEDPLUS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹6,892 Cr	₹220 Cr	3.2%
FY2025	₹6,136 Cr	₹150 Cr	2.4%
FY2024	₹5,625 Cr	₹65 Cr	1.2%
FY2023	₹4,558 Cr	₹50 Cr	1.1%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q2	₹1,880 Cr	₹33 Cr	1.8%
2026Q1	₹1,864 Cr	₹64 Cr	3.4%
2025Q4	₹1,806 Cr	₹58 Cr	3.2%
2025Q3	₹1,679 Cr	₹56 Cr	3.3%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Request To Ignore Inadvertent Filing Of Investor Presentation
Request to Ignore Inadvertent Filing of Investor Presentation
BSE7/22/2026
Update Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
BSE7/22/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.